

## TAZ (H-70): sc-48805



The Power to Question

## BACKGROUND

The transcriptional co-activator with PDZ-binding motif (TAZ) is a 14-3-3-binding molecule. The highly conserved and ubiquitously expressed 14-3-3 proteins regulate differentiation, cell cycle progression and apoptosis by binding intracellular phosphoproteins involved in signal transduction. TAZ may link events at the plasma membrane and cytoskeleton to nuclear transcription in a manner that can be regulated by 14-3-3. TAZ shares homology with the WW domain of Yes-associated protein (YAP) and functions as a transcriptional co-activator by binding to the PPXY motif present on transcription factors. TAZ recognizes immunoreactive protein bands in lysates from MDCK, NIH-3T3 and 293T cells. In addition, COS7, Hep G2, CHO and HeLa cells express endogenous TAZ. 14-3-3 binding requires TAZ phosphorylation on a single Ser 89 residue, resulting in the inhibition of TAZ transcriptional co-activation through 14-3-3-mediated nuclear export.

## REFERENCES

1. Kanai, F., et al. 2000. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. *EMBO J.* 19: 6778-6791.
2. Fu, H., et al. 2000. 14-3-3 proteins: structure, function, and regulation. *Annu. Rev. Pharmacol. Toxicol.* 40: 617-647.
3. Garner, C., et al. 2000. PDZ domains in synapse assembly and signaling. *Trends Cell. Biol.* 7: 274-280.

## CHROMOSOMAL LOCATION

Genetic locus: WWTR1 (human) mapping to 3q25.1; Wwtr1 (mouse) mapping to 3 D.

## SOURCE

TAZ (H-70) is a rabbit polyclonal antibody raised against amino acids 161-230 mapping within an internal region of TAZ of human origin.

## PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## APPLICATIONS

TAZ (H-70) is recommended for detection of TAZ of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for TAZ siRNA (h): sc-38568, TAZ siRNA (m): sc-38569, TAZ shRNA Plasmid (h): sc-38568-SH, TAZ shRNA Plasmid (m): sc-38569-SH, TAZ shRNA (h) Lentiviral Particles: sc-38568-V and TAZ shRNA (m) Lentiviral Particles: sc-38569-V.


Molecular Weight of TAZ: 45 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200.


## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## DATA



TAZ (H-70): sc-48805. Western blot analysis of TAZ expression in HeLa whole cell lysate.



TAZ (H-70): sc-48805. Immunofluorescence staining of normal mouse liver frozen section showing nuclear staining (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded human gall bladder tissue showing nuclear and cytoplasmic staining of glandular cells (B).

## SELECT PRODUCT CITATIONS

1. Di Palma, T., et al. 2009. TAZ is a coactivator for Pax8 and TTF-1, two transcription factors involved in thyroid differentiation. *Exp. Cell Res.* 315: 162-175.
2. Liu, Y., et al. 2010. Taz-tead1 links cell-cell contact to zeb1 expression, proliferation, and dedifferentiation in retinal pigment epithelial cells. *Invest. Ophthalmol. Vis. Sci.* 51: 3372-3378.
3. de Cristofaro, T., et al. 2011. TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. *Eur. J. Cancer* 47: 926-933.
4. Matteucci, E., et al. 2012. Bone metastatic process of breast cancer involves methylation state affecting E-cadherin expression through TAZ and WWOX nuclear effectors. *Eur. J. Cancer* 49: 231-244.
5. Xie, M., et al. 2012. Prognostic significance of TAZ expression in resected non-small cell lung cancer. *J. Thorac. Oncol.* 7: 799-807.
6. Bendinelli, P., et al. 2013. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. *Eur. J. Cancer pii: S0959-S8049.*

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

**MONOS**  
Satisfaction  
Guaranteed

Try **TAZ (1F1): sc-293183**, our highly recommended monoclonal alternative to TAZ (H-70).